HSR&D Citation Abstract
Search | Search by Center | Search by Source | Keywords in Title
Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.
Kurella Tamura M, Gaussoin S, Pajewski NM, Zaharchuk G, Freedman BI, Rapp SR, Auchus AP, Haley WE, Oparil S, Kendrick J, Roumie CL, Beddhu S, Cheung AK, Williamson JD, Detre JA, Dolui S, Bryan RN, Nasrallah IM, SPRINT Research Group. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 Sep 17.
RATIONALE and OBJECTIVE:
The safety of intensive blood pressure (BP) targets is controversial for persons with chronic kidney disease (CKD). We studied the effects of hypertension treatment on cerebral perfusion and structure in individuals with and without CKD.
Neuroimaging substudy of a randomized trial.
SETTING and PARTICIPANTS:
A subset of participants in the Systolic Blood Pressure Intervention Trial (SPRINT) who underwent brain magnetic resonance imaging studies. Presence of baseline CKD was assessed by estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR).
Participants were randomly assigned to intensive (systolic BP < 120 mm Hg) versus standard (systolic BP < 140 mm Hg) BP lowering.
The magnetic resonance imaging outcome measures were the 4-year change in global cerebral blood flow (CBF), white matter lesion (WML) volume, and total brain volume (TBV).
A total of 716 randomized participants with a mean age of 68 years were enrolled; follow-up imaging occurred after a median 3.9 years. Among participants with eGFR < 60 mL/min/1.73 m (n = 234), the effects of intensive versus standard BP treatment on change in global CBF, WMLs, and TBV were 3.38 (95% CI, 0.32 to 6.44) mL/100 g/min, -0.06 (95% CI, -0.16 to 0.04) cm (inverse hyperbolic sine-transformed), and -3.8 (95% CI, -8.3 to 0.7) cm, respectively. Among participants with UACR > 30 mg/g (n = 151), the effects of intensive versus standard BP treatment on change in global CBF, WMLs, and TBV were 1.91 (95% CI, -3.01 to 6.82) mL/100 g/min, 0.003 (95% CI, -0.13 to 0.13) cm (inverse hyperbolic sine-transformed), and -7.0 (95% CI, -13.3 to -0.3) cm, respectively. The overall treatment effects on CBF and TBV were not modified by baseline eGFR or UACR; however, the effect on WMLs was attenuated in participants with albuminuria (P = 0.04 for interaction).
Measurement variability due to multisite design.
Among adults with hypertension who have primarily early kidney disease, intensive versus standard BP treatment did not appear to have a detrimental effect on brain perfusion or structure. The findings support the safety of intensive BP treatment targets on brain health in persons with early kidney disease.
SPRINT was funded by the National Institutes of Health (including the National Heart, Lung, and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute on Aging; and the National Institute of Neurological Disorders and Stroke), and this substudy was funded by the National Institutes of Diabetes and Digestive and Kidney Diseases.
SPRINT was registered at ClinicalTrials.gov with study number NCT01206062.